Role of incretin based therapies in the treatment of diabetic kidney disease

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Diabetic kidney disease (DKD), a serious microvascular complication of diabetes mellitus is a leading cause of end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality. Despite advancements in blood glucose and blood pressure (BP) control, ~20% to 40% of patients with diabetes mellitus develop DKD. Intensive glycaemic and BP control positively influence decline in estimated glomerular filtration rate and albuminuria, thereby delaying the onset and progression of diabetic nephropathy. Incretin based therapies namely glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used glucose lowering agents and have shown favorable renal outcomes in DKD.  This article discusses the extra-glycaemic properties of incretin based therapies and their renoprotective effects on components of the metabolic syndrome, including obesity, hypertension and dyslipidaemia; reduction in oxidative stress and inflammation; and increase in natriuresis.

About the authors

Paola Fioretto

Department of Medicine, University of Padova.

Author for correspondence.


Italy, Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.

Andrea Frascati


Supplementary files

There are no supplementary files to display.



Abstract: 19

Article Metrics

Metrics Loading ...



Copyright (c) Fioretto P., Frascati A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies